Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).The merger creates a biotech company focused on developing gene therapies for IRDs.The combined company will be renamed Opus Genetics, effective October 23, 2024, and trade on the Nasdaq under the “IRD” ticker, effective October 24, 2024.The combined company now has an expanded pipeline that includes multiple assets from its adeno-as ...